Alphabet's Verily announces partnerships with big pharma firms Novartis, Sanofi, Otsuka, and Pfizer as it moves into the clinical trials space
KEY POINTS — Pharma companies are looking to work with Verily, which is part of the Alphabet umbrella, as they try to find ways to modernize … Thanks: @chrissyfarr
Context & Ripple Effects
Verily has spent years converting Alphabet's life-sciences bet into an investable business: Temasek put in $800M for a minority stake and board seat in 2017, and just months before this announcement Silver Lake led a $1B round that added Alphabet CFO Ruth Porat and Egon Durban to the board. That capital was raised against a promise of commercial revenue beyond Google's balance sheet.
Landing four pharma majors at once — Novartis, Sanofi, Otsuka, and Pfizer — is the first concrete answer to where that revenue comes from: clinical trials, where drugmakers are actively hunting for ways to modernize recruitment and data collection. It also broadens a pipeline that already included talks with insurers about risk-sharing contracts and sensor-based consumer products.
First-order effects
- Novartis, Sanofi, Otsuka, and Pfizer gain a partner with Alphabet-scale data and device infrastructure for running trials, while Verily gets its first marquee pharma customer roster to justify the $1B+ raised from Silver Lake and Temasek.
Second-order effects
- A working trials business strengthens Verily's parallel push into insurance: the same patient-data infrastructure that serves pharma sponsors is what its proposed risk-bearing contracts with insurers would run on.
- The commercial traction is what later underwrites continued outside funding — by December 2020 Verily raises another $700M explicitly to expand its commercial businesses.
Third-order effects
- If the pattern holds, Alphabet's health arm becomes a paid infrastructure layer between drugmakers, insurers, and patients — a regulated-data business funded increasingly by outside investors rather than Alphabet itself, with Temasek and Silver Lake holding governance seats as the model matures.
The trend: Big Tech health units are pivoting from open-ended research moonshots to commercial services sold to pharma and insurers, with sovereign-wealth and private-equity capital replacing parent-company patience.